WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Bichette has 4 hits, Berríos snaps 4
2 Laotian teens return home after release from Myanmar scam casino — Radio Free Asia
In many African countries, abortions are legal. But information and access can be hard to come by
Lawsuit seeks to force ban on menthol cigarettes after delays by Biden
Russian theater director and playwright go on trial over a play authorities say justifies terrorism
Thailand ready for any scenario on Myanmar border, foreign minister says — Radio Free Asia
US officials warn of increase in bacterial illnesses that can lead to meningitis and possibly death
Posts distort former Virginia governor’s comments on third trimester abortions
Kosovo prepares a new draft law on renting prison cells to Denmark after the first proposal failed
Two bodies found in search for Sydney couple Jesse Baird and Luke Davies
‘The Blue Angels,’ filmed for IMAX, puts viewers in the ‘box’ with the elite flying squad
$1.50 for a coffee? The viral street ‘cafe’ run by a homeless man